Researchers identify information gaps about opioid antidote naloxone

November 27, 2017, Oregon Health & Science University

The nation's opioid epidemic kills 91 people a day, according to the U.S. Centers for Disease Control and Prevention. The death toll would be even higher, were it not for emergency responders' heavy reliance on naloxone as an antidote that rapidly reverses the effects of overdose.

However, a new systematic review of evidence by clinicians and researchers at OHSU in Portland, Oregon, reveals important gaps in knowledge about the safety and effectiveness of widespread off-label use of among patients, families, friends and . The study published today in the Annals of Internal Medicine.

"Naloxone is effective, but we really need to know the best way to administer it," said senior author Roger Chou, M.D., director of the Pacific Northwest Evidence-based Practice Center at OHSU. "This has both cost and clinical implications."

The U.S. Food & Drug Administration in 2015 approved two prescription versions of naloxone - an auto-injector and a nasal spray formulation. However, many first responders have been using the less-concentrated injectable formulations of naloxone to reverse the effects of opioids. In those emergency situations, they administer it through the nose.

Such off-label permutations have been effectively used by law enforcement treating unconscious victims, but it is uncertain how much of the non-approved formulation of naloxone is absorbed and how reliably it is administered. Both of these factors could impact the effectiveness of off-label administration of naloxone compared with the more recent FDA-approved versions.

"The majority of naloxone being administered nasally is probably the non-approved formulation," said co-author Mohamud Daya, M.D., professor of emergency medicine in the OHSU School of Medicine. "The sad thing is, we don't know much about the new formulations. They've not actually been well studied in the way that you'd want them to be in a large population of patients."

One thing clinicians and first responders do know: The new FDA-approved formulations are expensive. The auto-injector, for example, carries a price tag exceeding $4,000.

Researchers reviewed 13 published studies to determine how the route of administration and dosing outside the hospital affects mortality, reversal of overdose symptoms and harm. The evidence appeared to show similar effectiveness between the intramuscular and intranasal delivery for heroin or prescription opioid overdose, but the intranasal naloxone studied was at a concentration different than the FDA-approved nasal formulation. Researchers also noted that little is known about the efficacy and safety of off-label use of naloxone for treating overdoses related to newly emerging illicit uses of more powerful opioids such as fentanyl and fentanyl derivatives.

"The off label may be fine for most overdoses related to standard heroin or prescription opioids, but may not be strong enough for these other drugs," Chou said.

It's important for new research to examine the effect of these off-label uses, he said.

"These jury-rigged intranasal devices have not been tested the same way," Chou said. "The fact that we have no evidence on the off-label uses for these devices is concerning, especially because many first responders feel compelled to use them because of the cost differences."

Explore further: Reversing opioid overdose: Concentrated naloxone nasal spray as good as injection

More information: Annals of Internal Medicine (2017). DOI: 10.7326/M17-2224

Related Stories

Reversing opioid overdose: Concentrated naloxone nasal spray as good as injection

November 16, 2017
A new study published by the scientific journal Addiction has found that a concentrated 2mg intranasal naloxone spray delivers naloxone as effectively, over the critical first 15 minutes, as the standard 0.4mg intramuscular ...

How to obtain and use the 'angel' therapeutic Naloxone

July 18, 2017
It's a terrifying scenario that's become all-too-real in the age of the opioid epidemic: a person lying lifeless, not breathing, because of an opioid overdose.

Improvised naloxone nasal sprays lack evidence of absorption and effect

February 4, 2016
Naloxone hydrochloride is a medication that can reverse the effects of an opioid overdose. First responders (peers, family, police, etc.) may prefer nasal sprays to injectable naloxone, which has led to widespread use of ...

FDA approves nasal spray to reverse narcotic painkiller overdose

November 19, 2015
(HealthDay)—A nasal spray that treats narcotic painkiller and heroin drug overdoses has been approved by the U.S. Food and Drug Administration.

Naloxone—an antidote to opioid overdose

August 31, 2016
Naloxone is an opioid antagonist, used as an "antidote" for opioid overdose which includes heroin, and opioid pain medicines such as morphine, fentanyl and codeine. It has been used since the 1970s by ambulance services and ...

Recommended for you

Shortcut strategy for screening compounds with clinical potentials for drug development

December 4, 2018
Developing a new drug often takes years and costs hundreds of millions of dollars. A shortcut has now been reported in a study led by City University of Hong Kong (CityU), which can potentially reduce the time and costs of ...

Drug wholesalers drove fentanyl's deadly rise, report concludes

December 4, 2018
Fentanyl, a powerful synthetic opioid implicated in nearly 29,000 overdose deaths in the United States last year, most likely spread because of heroin and prescription pill shortages, and also because it was cheaper for drug ...

Global review reports on administration of children's antibiotics

December 4, 2018
Researchers analyzing the sales of oral antibiotics for children in 70 high- and middle-income countries found that consumption varies widely from country to country with little correlation between countries' wealth and the ...

Opioid prescriptions from dentists linked to youth addiction risk

December 3, 2018
Teens and young adults who receive their initial opioid prescriptions from their dentists or oral surgeons are at increased risk for opioid addiction in the following year, a study from the Stanford University School of Medicine ...

Rise in meth and opioid use during pregnancy

November 29, 2018
Amphetamine and opioid use in pregnancy increased substantially over the last decade in the United States, a new Michigan Medicine-led study finds. And a disproportionate rise occurred in rural counties.

Mouse model aids study of immunomodulation

November 19, 2018
Because mice do not respond to immunomodulatory drugs (IMiDs), preclinical therapeutic and safety studies of the effects of IMiDs have not been possible in existing types of mice. This has led to an inability to accurately ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.